Active Ingredient History

NOW
  • Now
Oxymorphone is an analgesic that is FDA approved for the treatment of moderate to severe pain. It is also indicated for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction. Oxymorphone (brand names Opana, Numorphan, Numorphone) is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Adverse reactions (≥ 2% of patients): seen with the immediate release tablet formulation Nausea, pyrexia, somnolence, vomiting, pruritus, headache, dizziness, constipation, and confusion. Concomitant use with serotonergic drugs may result in serotonin syndrome. Avoid use of mixed agonist/antagonist and partial agonist opioid analgesics with Opana because they may reduce analgesic effect of Opana or precipitate withdrawal symptoms.   NCATS

  • SMILES: CN1CC[C@]23[C@H]4Oc5c(O)ccc(C[C@@H]1[C@]2(O)CCC4=O)c35
  • InChIKey: UQCNKQCJZOAFTQ-ISWURRPUSA-N
  • Mol. Mass: 301.34
  • ALogP: 0.75
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$0.2499 - $15.4795
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

14-hydroxydihydromorphinone | dihydrohydroxymorphinone | en3202 | numorphan | opana | opana er | oximorphonum | oxymorphine | oxymorphone | (-)-oxymorphone | oxymorphone hcl | oxymorphone hydrochloride

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue